Skip to main content

OrbiMed — Portfolio, Page 8

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

289
Companies
$23.6B
Total invested
$104.0M
Avg. check
12
Industries
Biotechnology 22Health Care 16Medical 13Therapeutics 10Pharmaceutical 6Biopharma 6+6 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 169192 of 289
Alpheus Medical
May 2025

Alpheus Medical provides a novel sonodynamic therapy platform targeting solid body cancers.

Biotechnology · Oakdale$52.0M Series B
Sirius Therapeutics
May 2025

Sirius Therapeutics is an innovative biotechnology company that focuses on RNAi therapies for cardiovascular diseases.

Biotechnology · San Diego$50.0M Series B
Fore Biotherapeutics
May 2025

Fore Biotherapeutics is a precision oncology company specializing in cancer therapies guided by functional genomics.

Biotechnology · Philadelphia$40.2M Series D
Rimag
April 2025

Rimag is a Shenzhen-based medical imaging service provider.

Cloud Data Services · Beijing$25.1M Post Ipo Equity
RayThera
April 2025

RayThera is dedicated to developing small molecule therapies specifically targeting unmet needs in immunology.

Biotechnology · San Diego$110.0M Series A
Lomond Therapeutics
March 2025

Lomond Therapeutics creates pharmacological platforms that target escape mutations.

Biopharma · San Diego$20.0M Series Unknown
Curevo
March 2025

Curevo is a clinical-stage biotechnology company developing next-generation, non-mRNA vaccines for infectious diseases.

Biopharma · Bothell$110.0M Series B
Stratus Therapeutics
March 2025

Stratus Therapeutics develops off-the-shelf hematopoietic stem cell therapies to treat severe and life-threatening diseases.

Biotechnology · Cambridge$50.0M Series A
Aer Therapeutics
February 2025

Aer Therapeutics, a clinical-stage biopharmaceutical company developing therapeutic solutions for muco-obstructive lung diseases.

Biotechnology · Raleigh$5.0M Series Unknown
Helicore Biopharma
January 2025

Helicore Biopharma is a biopharmaceutical company that discovers and develops novel weight-loss therapeutics.

Biopharma · San Mateo$65.0M Series A
89bio
January 2025

89bio is a biopharmaceutical company that develops clinical-stage therapies for liver and cardiometabolic diseases.

Biopharma · San Francisco$287.5M Post Ipo Equity
Third Harmonic Bio
January 2025

Third Harmonic Bio is a clinical-stage company developing a first-in-class, highly selective, and oral kit inhibitor.

Biotechnology · Cambridge$3.9M Post Ipo Equity
Aerin Medical
January 2025

Aerin Medical is a health technology company that develops therapeutic devices to improve nasal breathing.

Biotechnology · Mountain View$32.5M Undisclosed
Verdiva Bio
January 2025

Verdiva Bio creates cutting-edge treatments that improve results for patients with obesity and cardiometabolic diseases.

Biotechnology · London$411.0M Series A
Ottimo Pharma
December 2024

Ottimo Pharma develops innovative cancer therapies using PD1-VEGFR2 antibodies.

Biotechnology · Sandwich$140.0M Series A
SiteOne Therapeutics
December 2024

SiteOne Therapeutics develops groundbreaking non-opioid treatments for acute, neuropathic, visceral, and musculoskeletal pain.

Biotechnology · South San Francisco$100.0M Series C
Janux Therapeutics
December 2024

Janux Therapeutics develops immunotherapies that generates immune responses to prevent tumors and not affecting a patient’s healthy tissue.

Biotechnology · La Jolla$350.0M Post Ipo Equity
ADCendo
November 2024

ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs.

Biotechnology · Copenhagen$135.0M Series B
Avalo Therapeutics
November 2024

Avalo Therapeutics is a clinical-stage biopharmaceutical company.

Biotechnology · Rockville$69.4M Post Ipo Equity
Harmony Biosciences
October 2024

Harmony Biosciences is a pharmaceutical company that develops and commercializes novel therapies for rare neurological disorders.

Biopharma · Plymouth Meeting$248.0M Post Ipo Secondary
Triveni Bio
October 2024

Triveni Bio is a a biotech company that develops functional antibodies targeting immunological and inflammatory disorders.

Biotechnology · Watertown$115.0M Series B
Convergent Therapeutics
September 2024

Convergent Therapeutics is a pharmaceutical company that focuses on developing radiopharmaceutical therapies for prostate cancer.

Health Care · Cambridge$40.0M Series A
Pathalys Pharma
August 2024

Pathalys is a clinical biopharmaceutical company that develops therapeutics that improve late-stage chronic kidney disease.

Biopharma · Raleigh$105.0M Series B
scPharmaceuticals
August 2024

ScPharmaceuticals is a biopharmaceutical company developing a portfolio of transformative pharmaceutical products for subcutaneous delivery.

Biotechnology · Lexington$125.0M Post Ipo Debt

Where OrbiMed invests

Biotechnology22
Health Care16
Medical13
Therapeutics10
Pharmaceutical6
Biopharma6

About OrbiMed's portfolio

How many companies has OrbiMed invested in?

OrbiMed has invested in 289 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does OrbiMed invest in?

OrbiMed's top investment sectors include Biotechnology, Health Care, Medical, Therapeutics, Pharmaceutical. The firm invests across 12 different industry categories.

What is OrbiMed's largest investment?

Among tracked funding rounds, Verdiva Bio received $411.0M in a Series A round. OrbiMed's total known invested capital is $23.6B.

What is the average investment size for OrbiMed?

OrbiMed's average investment size is $104.0M across its portfolio of 289 companies.

What are OrbiMed's most recent investments?

Recent OrbiMed portfolio additions include Alpheus Medical, Sirius Therapeutics, Fore Biotherapeutics, Rimag, RayThera. These companies were founded in 2020 or later.

Reach the founders behind these 289 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →